Lilly's Zyprexa: A Victim of Its Past Success
This article was originally published in RPM Report
Executive Summary
Antipsychotics in general-and Lilly's Zyprexa in particular-may be the products taking the biggest hit from health care reform. The only thing worse was the alternative.